ArticleFrontiers in public health2026
Development and internal validation of an interpretable machine learning model for predicting dialysis risk in patients with stage 3-4 chronic kidney disease.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinicians need practical tools to identify chronic kidney disease (CKD) patients at highest short-term risk of dialysis using only routine clinical data. Methods: We retrospectively analyzed 400 adults with CKD stages 3-4 treated at The Central Hospital of Wuhan (2022-2024). Incident hemodialysis during follow-up was the outcome. From 64 candidate variables, LASSO logistic regression embedded within 10-fold cross-validation selected predictors spanning renal, hematologic, and metabolic domains. Ten machine learning models were trained and evaluated using nested cross-validation; temporal validation was performed on a 2024 hold-out set. Performance was summarized as mean ± SD with 95% confidence intervals. Results: After correcting for data leakage, the Random Forest model demonstrated excellent discrimination with an AUC of 0.988 (95% CI: 0.974-1.003), accuracy of 0.965 (95% CI: 0.941-0.989), and recall of 0.970 (95% CI: 0.926-1.015). XGBoost and ANN showed comparable AUCs (0.987 and 0.985, respectively). Temporal validation yielded perfect discrimination (AUC = 1.000, recall = 1.000). Subgroup analysis showed consistent performance across sex, age, and diabetes strata. SHAP analysis identified creatinine, urine microalbumin, and eGFR as key predictors, with evidence of interaction between proteinuria and erythropoietic dysfunction. Conclusion: A model based on widely available clinical tests accurately predicts 12-month dialysis risk in stage 3-4 CKD patients. Its high performance and interpretability support potential use for early risk stratification in real-world nephrology practice, without requiring novel biomarkers or longitudinal monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.